Jim Cramer on TG Therapeutics: “You Should Buy the Stock”

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 14 stocks Jim Cramer recently looked at. When a caller inquired about the company during the lightning round, Cramer stated:

“I remember when Mike Weiss was an analyst. I always loved the man. I love him now. I think you should buy the stock.”

Jim Cramer on TG Therapeutics: "You Should Buy the Stock"

A scientific researcher holding a petri dish containing a glycoengineered monoclonal antibody.

TG Therapeutics, Inc. (NASDAQ:TGTX) develops and commercializes therapies for B-cell mediated diseases, and it offers BRIUMVI for multiple sclerosis and is advancing a pipeline of monoclonal antibodies and kinase inhibitors targeting autoimmune conditions and blood cancers. ClearBridge Investments stated the following regarding TG Therapeutics, Inc. (NASDAQ:TGTX) in its Q4 2024 investor letter:

“2024 proved a particularly active year for new idea generation: we added 23 new investments while exiting 29 due to a variety of considerations, including acquisitions, market capitalization constraints, and our assessment of forward return potential. While many of the new investments we made during the year are of relatively modest size, we will continue to build these positions over time provided company execution and end market prospects remain intact. In the fourth quarter we initiated five new investments: Oscar Health,TG Therapeutics, Inc. (NASDAQ:TGTX), Clearwater Analytics, Fluor and Modine.

TG Therapeutics is a commercial-stage biotechnology company focused on multiple sclerosis (MS), a significant chronic disease end market. Its lead product, Briumvi, has the potential to grow its market share significantly within the largest drug class in the $8 billion MS market.”

While we acknowledge the potential of TGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.